For example, Dabritz et al. analysed the presence of KRAS in the plasma of 56 patients with pancreatic adenocarcinoma and the expression of CA19-9 and obtained a sensitivity of 91% [156]. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.